Published in Nat Med on January 23, 2005
DC-based cancer vaccines. J Clin Invest (2007) 3.81
Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res (2013) 1.95
Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell (2014) 1.55
Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy (2010) 1.04
Immunological synapse formation inhibits, via NF-kappaB and FOXO1, the apoptosis of dendritic cells. Nat Immunol (2009) 1.01
Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma. PLoS One (2009) 1.01
A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol (2011) 0.94
A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Invest (2011) 0.94
Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transfer. PLoS One (2013) 0.89
Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system. Mediators Inflamm (2012) 0.85
Tobacco mosaic virus efficiently targets DC uptake, activation and antigen-specific T cell responses in vivo. Vaccine (2014) 0.82
Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvant. Mol Ther (2012) 0.81
Dendritic cells differentiate into osteoclasts in bone marrow microenvironment in vivo. Blood (2009) 0.81
Design of CD40 agonists and their use in growing B cells for cancer immunotherapy. Int Rev Immunol (2012) 0.81
Inhibition of SIRPα in dendritic cells potentiates potent antitumor immunity. Oncoimmunology (2016) 0.79
EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine. J Leukoc Biol (2011) 0.78
The E3 ligase c-Cbl regulates dendritic cell activation. EMBO Rep (2011) 0.78
Emerging vaccine therapy approaches for prostate cancer. Rev Urol (2010) 0.78
Levels of CD40 expression on dendritic cells dictate tumour growth or regression. Clin Exp Immunol (2007) 0.77
Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies. Blood (2016) 0.76
Activation of antigen-exposed iMC-DCs at the "right place" and "right time" promotes potent anti-tumor immunity. Oncoimmunology (2012) 0.75
Human IDO-competent, long-lived immunoregulatory dendritic cells induced by intracellular pathogen, and their fate in humanized mice. Sci Rep (2017) 0.75
MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine Immunogenicity. PLoS One (2016) 0.75
Enhanced immunity against hepatoma induced by dendritic cells pulsed with Hsp70-H22 peptide complexes and CD40L. J Cancer Res Clin Oncol (2012) 0.75
Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol Res (2017) 0.75
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ (2006) 9.04
Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev (2009) 6.66
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
Shared decision making: a model for clinical practice. J Gen Intern Med (2012) 5.87
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA (2013) 4.17
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
An inducible caspase 9 safety switch for T-cell therapy. Blood (2005) 2.93
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72
The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol (2003) 2.59
Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell (2007) 2.48
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology (2007) 2.23
Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res (2008) 2.18
The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. Clin Infect Dis (2012) 2.16
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol (2007) 2.06
Hematoma resolution as a target for intracerebral hemorrhage treatment: role for peroxisome proliferator-activated receptor gamma in microglia/macrophages. Ann Neurol (2007) 2.05
An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol (2006) 2.04
Polymorphisms of the androgen receptor gene and hormonal contraceptive induced provoked vestibulodynia. J Sex Med (2014) 1.99
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res (2008) 1.90
Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol (2004) 1.87
Substance abuse vaccines. Ann N Y Acad Sci (2008) 1.74
Paths of FGFR-driven tumorigenesis. Cell Cycle (2009) 1.63
Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. J Cell Biol (2002) 1.61
Anti-Müllerian hormone as a predictor of IVF outcome. Reprod Biomed Online (2007) 1.57
Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol (2004) 1.55
Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res (2004) 1.45
Rosuvastatin-warfarin drug interaction. Lancet (2004) 1.44
Power Doppler assessment of follicle vascularity at the time of oocyte retrieval in in vitro fertilization cycles. Fertil Steril (2008) 1.44
Reliability of remembered International Index of Erectile Function domain scores in men with localized prostate cancer. Urology (2005) 1.43
Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol (2006) 1.42
Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer (2004) 1.41
Herbal/hormonal dietary supplement possibly associated with prostate cancer progression. Clin Cancer Res (2008) 1.39
Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto. J Altern Complement Med (2013) 1.38
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology (2008) 1.32
Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut (2006) 1.26
Vaccines for cocaine abuse. Hum Vaccin (2009) 1.23
Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol (2002) 1.21
Intravital imaging of fluorescent markers and FRET probes by DNA tattooing. BMC Biotechnol (2007) 1.19
Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res (2003) 1.18
Anomalies of the wolffian duct derivatives encountered at radical prostatectomy. Rev Urol (2005) 1.18
Predictors of prostate cancer after initial negative systematic 12 core biopsy. J Urol (2004) 1.17
T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther (2010) 1.17
Notch and TGFβ form a reciprocal positive regulatory loop that suppresses murine prostate basal stem/progenitor cell activity. Cell Stem Cell (2012) 1.16
Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther (2011) 1.16
Unsteady behavior of flow in a scaled-up vocal folds model. J Acoust Soc Am (2007) 1.14
Turbulence drives microscale patches of motile phytoplankton. Nat Commun (2013) 1.13
The future of vaccines in the management of addictive disorders. Curr Psychiatry Rep (2007) 1.11
Activation of initiator caspases through a stable dimeric intermediate. J Biol Chem (2002) 1.09
Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Read (2002) 1.08
Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res (2003) 1.07
Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J Urol (2004) 1.07
Radiation therapy after radical prostatectomy: why patience is a virtue! The case for salvage radiation therapy. Rev Urol (2002) 1.07
Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. J Urol (2004) 1.07
Microcosting versus DRGs in the provision of cost estimates for use in pharmacoeconomic evaluation. Expert Rev Pharmacoecon Outcomes Res (2002) 1.07
T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood (2011) 1.07
Targeted expression of c-Src in epidermal basal cells leads to enhanced skin tumor promotion, malignant progression, and metastasis. Cancer Res (2003) 1.06
An inducible system for the study of FGF signalling in early amphibian development. Dev Biol (2003) 1.05
Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care? Eur J Heart Fail (2003) 1.04
Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res (2003) 1.02
Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. Cancer Res (2003) 1.02
Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate (2009) 1.02
A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum Dis (2011) 1.01
Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. J Urol (2012) 1.00
Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clin Trials (2009) 0.99
Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol (2002) 0.99
Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol (2005) 0.99
Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol (2004) 0.99
Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res (2007) 0.98
Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology (2004) 0.98
Level of endothelial cell apoptosis required for a significant decrease in microvessel density. Exp Cell Res (2007) 0.98
Wnt and Notch pathways have interrelated opposing roles on prostate progenitor cell proliferation and differentiation. Stem Cells (2011) 0.97
Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer. Prostate (2005) 0.97
Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol (2004) 0.95
Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol (2004) 0.95
Activation of Wnt signaling by chemically induced dimerization of LRP5 disrupts cellular homeostasis. PLoS One (2012) 0.95
Regulated apoptosis of genetically modified hematopoietic stem and progenitor cells via an inducible caspase-9 suicide gene in rhesus macaques. Stem Cells (2015) 0.94
Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. Clin Cancer Res (2008) 0.94
A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Invest (2011) 0.94
The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health (2012) 0.93
Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis. Pharmacoeconomics (2010) 0.93
The phosphatase SRC homology region 2 domain-containing phosphatase-1 is an intrinsic central regulator of dendritic cell function. J Immunol (2011) 0.93
Drug expenditure in Ireland 1991-2001. Ir Med J (2003) 0.90
A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting. Pharmacoeconomics (2009) 0.89
FGFR1-WNT-TGF-β signaling in prostate cancer mouse models recapitulates human reactive stroma. Cancer Res (2013) 0.89
Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine (2008) 0.89
Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara® for prostate cancer therapy. J Gene Med (2011) 0.88
Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res (2002) 0.88